Clinical Trial Update: Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update reports on the 24-week effectiveness of Abilify (aripiprazole) for bipolar disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Korea Otsuka Pharmaceutical Co., Ltd. | Conditions: Bipolar Disorder | Phase 4 | Status: COMPLETED